XenoPort, GSK gain US FDA nod for Horizant in shingles pain
This article was originally published in Scrip
Executive Summary
The US FDA has approved XenoPort's and GlaxoSmithKline's application for Horizant (gabapentin enacarbil) extended release as a therapy for adults to manage postherpetic neuralgia (PHN), a chronic type of neuropathic pain that can follow the resolution of shingles.